Preserving insulin secretion in diabetes by inhibiting VDAC1 overexpression and surface translocation in β-cells
. A, B, Representative Western blots and fold change by densitometry normalized to β-actin (mean ± SEM) for VDAC1 (A) and VDAC2 (B) in islet extracts from non-diabetic (ND) and T2D donors (n = 8 donors in each group). C, Correlation between islet VDAC1 mRNA and donor HbA1c in ND+T2D excluding the four metformin-treated (n=26), (cf. Figure 1B insert), P<0.005. D, Correlation between islet VDAC2 mRNA and donor HbA1c in ND+T2D excluding the four metformin-treated (n=26) (cf. Figure 1D insert), *P<0.05. E, Alignment of the human, mouse and rat VDAC1genes. Note the difference in exon 1 in mouse on the one hand and human and the rat on the other. Alignments to the human VDAC1 gene on chromosome 5 were visualized using the Integrative Genomics Viewer. F, Scheme of the two most abundant VDAC1 transcript variants (ENST00000395044 and ENST00000395047) in human islets analyzed by RNA sequencing. G, Increased expression of VDAC1 transcript variant ENST00000395047 in ND islets and those of donors with impaired glucose tolerance (IGT) and T2D as analyzed by RNA sequencing (ND=181 donors, IGT=19, T2D=16 donors). H, VDAC1 and VDAC2 mRNA expression in human islets cultured at 5, 10 or 20 mM glucose for 72h. 7) . Aberrant localization of VDAC1 and effects of its blockade in db/db mouse islets. A, Representative confocal images showed that Vdac1 is expressed predominantly on the surface of β-cells in db/db mouse islets (scale bar: 10 um). B, Surface and cytosolic mean intensity of Vdac1 in β-cells were measured. Results from 23 (c57/bl) and 25 (db/db) islets isolated from 8 mice of each genotype are shown. Data are mean ± SEM. C, Vdac1 mRNA measured by qPCR in c57/bl and db/db mouse islets. D,E, VDAC1 antibody (10 nM), metformin, AKOS022075291 and VBIT-4 (all at 20 μΜ) do not affect ATP content (D) or GSIS (E, in c57/bl) islets. Islets isolated from four c57/bl mice were incubated separately in a single experiment. Data are mean ± SEM. F, ATP content in isolated islets from non-diabetic (ND) and T2D organ donors after culture for 72h at 5 (5G) or 20 mM glucose (20G) in the presence or absence of VDAC1 antibody (10 nM) (VDAC1ab) or metformin (Met, 20 μM) . Note the improved ATP content in glucotoxic condition and T2D islets. Data are mean ± SEM of 5 non-diabetic and 3 T2D donors. G, Cellular reductive capacity (formazone production) measured in non-diabetic or T2D islets (F) after 5 or 20 mM glucose culture as in F. Mean ± SEM of 5 nondiabetic and 3 T2D donors are shown. H, Effect on insulin secretion of different concentrations of VBIT-4 added during 1 h incubation in the presence of 1 or 16.7 mM glucose (16.7G) in ND human islets. Mean+SEM of two experiments with 1 donor each. I, Body weight of db/db and c57/bl mice treated with VBIT-4 (25 mg/kg ip) or vehicle for 5 weeks. J, Plasma insulin during IPGTT (2 g/kg) of the experiments shown in Fig. 7H . Mean±SEM 12 db/db in each group and 5-6 c57/bl in each group is shown. K, Insulin sensitivity in db/db mice is improved by VBIT-4. HOMA-IR was calculated from the results shown in figures 7H and S7J. Mean+SEM of 12 db/db (each group) and 5-6 c57/bl mice are shown. L, Glucose-stimulated insulin secretion from isolated islets of db/db mice treated for 5 weeks with daily IP injections of VBIT-4 (25 mg/kg) or vehicle. The islets were incubated for 1h at 1 (1G) or 16.7 mM glucose (16.7G). Data are mean ± SEM of 6 mice in each group with 2 technical replicates. * p<0.05, ** p<0.01, *** p<0.001. M, Schematic illustration of VDAC1 plasma membrane expression in β-cells of T2D islets causing cellular ATP depletion with consequent blunting of GSIS. Inhibitors of VDAC1 (VDAC1 Antibody, VBIT-4, AKOS and metformin) block ATP depletion when added acutely and restore GSIS. Moreover, 72h presence of these inhibitors prevents the VDAC1 upregulation and mistargeting to the β-cell plasma membrane under glucotoxic conditions. This effect also provides an explanation for the protracted increase in blood glucose of db/db mice after cessation of VBIT-4 treatment (cf. Figure 7G ). 
